For instance, while TGF-β targeted agents like Trabedersen and Galunisertib have shown promise in combating ovarian cancer [79], DFO, as an iron chelator, is considered to be a tumor suppressor for the disease as well [8]. This evidence concerns the gene TGFB1 and neoplasm.